Literature DB >> 8498394

Value of a simple measure of estrogen status for improving the diagnosis of coronary artery disease in women.

Anthony P Morise1, Jyotsna N Dalal1, Robert D Duva1.   

Abstract

PURPOSE: To determine the potential impact of estrogen status on the pretest and postexercise test diagnostic accuracy of exercise testing. PATIENTS AND METHODS: The study comprised a total of 234 women and 326 men who underwent exercise testing followed by coronary angiography. We performed incremental logistic regression analysis of pretest (age, symptoms, smoking, diabetes, cholesterol level) with and without estrogen status (defined according to menopausal and oral estrogen status) and exercise test (two ST-segment and three non-ST-segment) variables separately for men and women. Outcomes were assessed by receiver operating characteristic (ROC) curve area analysis.
RESULTS: Estrogen status was an independent pretest predictor of angiographic coronary disease. Pretest ROC curve areas: women without estrogen status = 0.79, women with estrogen status = 0.85, men = 0.78 (women with estrogen status versus other groups, p < 0.001). Postexercise test ROC curve areas: women without estrogen status = 0.83, women with estrogen status = 0.87, men = 0.88 (women without estrogen status versus other groups, p < 0.001).
CONCLUSION: Consideration of estrogen status allowed for a significant improvement in the pretest clinical diagnosis of coronary disease in women. When these improvements were added to the results of exercise testing, the diagnostic accuracy of the combined clinical and exercise test data was similar for men and women. Estrogen status may be an important diagnostic clinical variable in women with suspected coronary disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498394     DOI: 10.1016/0002-9343(93)90083-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  A pretest prognostic score to assess patients undergoing exercise or pharmacological stress testing.

Authors:  Anthony Morise; Matthew Evans; Farrukh Jalisi; Rajendra Shetty; Marc Stauffer
Journal:  Heart       Date:  2007-02       Impact factor: 5.994

Review 2.  Assessing and Modifying Coronary Artery Disease Risk in Women.

Authors:  Amy Sarma; Nandita S Scott
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

Review 3.  Assessing patients with possible heart disease using scores.

Authors:  K Shetler; A Karlsdottir; V Froelicher
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

4.  Risk stratification of CAD with SPECT-MPI in women with known estrogen status.

Authors:  Nitesh Sood; Fawad A Kazi; Justin B Lundbye; Deborah Katten; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952

Review 5.  The prognostic value of non-perfusion variables obtained during vasodilator stress myocardial perfusion imaging.

Authors:  Navkaranbir S Bajaj; Siddharth Singh; Ayman Farag; Stephanie El-Hajj; Jack Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-03-03       Impact factor: 5.952

Review 6.  American Society of Nuclear Cardiology consensus statement: Task Force on Women and Coronary Artery Disease--the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women [correction].

Authors:  Jennifer H Mieres; Leslee J Shaw; Robert C Hendel; D Douglas Miller; Robert O Bonow; Daniel S Berman; Gary V Heller; Jennifer H Mieres; C Noel Bairey-Merz; Daniel S Berman; Robert O Bonow; Jean M Cacciabaudo; Gary V Heller; Robert C Hendel; Maria C Kiess; D Douglas Miller; Donna M Polk; Leslee J Shaw; Paola E Smanio; Mary N Walsh
Journal:  J Nucl Cardiol       Date:  2003 Jan-Feb       Impact factor: 5.952

Review 7.  North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. North of England Stable Angina Guideline Development Group.

Authors: 
Journal:  BMJ       Date:  1996-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.